RADX Shares Slip Ahead of Cancer-Imaging Update
Radiopharm Theranostics’ U.S. shares slipped a bit in light Nasdaq trading on Thursday. Investors are waiting for more updates on the Australian biotech’s top cancer-imaging project. The American depositary shares closed at $4.52, off 6 cents. The last trade was at 9:33 a.m. EDT and showed just 325 shares. That’s thin volume compared with the 161,513-share average daily volume Zacks cited earlier this month.